"Lactones" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Cyclic esters of hydroxy carboxylic acids, containing a 1-oxacycloalkan-2-one structure. Large cyclic lactones of over a dozen atoms are MACROLIDES.
| Descriptor ID |
D007783
|
| MeSH Number(s) |
D02.540
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Lactones".
Below are MeSH descriptors whose meaning is more specific than "Lactones".
This graph shows the total number of publications written about "Lactones" by people in this website by year, and whether "Lactones" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2010 | 1 | 0 | 1 |
| 2012 | 1 | 0 | 1 |
| 2016 | 0 | 1 | 1 |
| 2017 | 14 | 3 | 17 |
| 2018 | 4 | 2 | 6 |
| 2019 | 4 | 0 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Lactones" by people in Profiles.
-
Structure of the SARS-CoV-2 Nsp1/5'-Untranslated Region Complex and Implications for Potential Therapeutic Targets, a Vaccine, and Virulence. J Phys Chem Lett. 2020 Nov 19; 11(22):9659-9668.
-
Unravelling high-affinity binding compounds towards transmembrane protease serine 2 enzyme in treating SARS-CoV-2 infection using molecular modelling and docking studies. Eur J Pharmacol. 2021 Jan 05; 890:173688.
-
ADMET profile and virtual screening of plant and microbial natural metabolites as SARS-CoV-2 S1 glycoprotein receptor binding domain and main protease inhibitors. Eur J Pharmacol. 2021 Jan 05; 890:173648.
-
MEDT study of the 1,3-DC reaction of diazomethane with Psilostachyin and investigation about the interactions of some pyrazoline derivatives with protease (Mpro) of nCoV-2. J Mol Graph Model. 2021 01; 102:107763.
-
Proteinase-activated receptor 1: A target for repurposing in the treatment of COVID-19? Br J Pharmacol. 2020 11; 177(21):4971-4974.
-
Recommendations on diagnosis and treatment in hepatobiliary surgery under 2019-nCoV epidemic. Clin Res Hepatol Gastroenterol. 2020 09; 44(4):403-406.
-
Fool Me Twice? The Reemergence of Rofecoxib and the Orphan Drug Act. Ann Intern Med. 2019 10 15; 171(8):578-579.
-
Efficacy and safety of more potent antiplatelet therapy with vorapaxar in patients with impaired renal function. J Thromb Thrombolysis. 2019 Apr; 47(3):353-360.
-
Vorapaxar for secondary prevention in the elderly with peripheral artery disease: Insights from the TRA 2°P-TIMI 50 trial. Vasc Med. 2019 04; 24(2):159-161.
-
Personalized benefit-risk assessments combining clinical trial and real-world data provide further insights into which patients may benefit most from therapy: Demonstration for a new oral antiplatelet therapy. Pharmacoepidemiol Drug Saf. 2019 04; 28(4):443-451.